190 related articles for article (PubMed ID: 35285968)
1. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
3. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
[TBL] [Abstract][Full Text] [Related]
6. Aducanumab: Appropriate Use Recommendations Update.
Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S
J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
[TBL] [Abstract][Full Text] [Related]
8. Aducanumab: Appropriate Use Recommendations.
Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
[TBL] [Abstract][Full Text] [Related]
9. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
[TBL] [Abstract][Full Text] [Related]
10. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.
Howe MD; Britton KJ; Joyce HE; Pappas GJ; Faust MA; Dawson BC; Riddle MC; Salloway SP
J Prev Alzheimers Dis; 2023; 10(4):765-770. PubMed ID: 37874098
[TBL] [Abstract][Full Text] [Related]
11. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
[TBL] [Abstract][Full Text] [Related]
13. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
Urbach H; Linn J; Hattingen E; Fiebach J
Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
[TBL] [Abstract][Full Text] [Related]
15. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies.
Piazza F; Caminiti SP; Zedde M; Presotto L; DiFrancesco JC; Pascarella R; Giossi A; Sessa M; Poli L; Basso G; Perani D
Neurology; 2022 Sep; 99(12):e1265-e1277. PubMed ID: 35940900
[TBL] [Abstract][Full Text] [Related]
16. MR imaging features of amyloid-related imaging abnormalities.
Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
[TBL] [Abstract][Full Text] [Related]
18. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
[TBL] [Abstract][Full Text] [Related]
19. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]